Patents by Inventor Hwa Kyoung Lee

Hwa Kyoung Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230242670
    Abstract: The present invention relates to an anti-ROS1 antibody improved in specificity for ROS1 and a use thereof and, more particularly, provides an anti-ROS1 antibody or an antigen-binding fragment thereof and a use thereof in cancer diagnosis
    Type: Application
    Filed: March 6, 2018
    Publication date: August 3, 2023
    Inventors: Junho CHUNG, Eugene C. Yl, Ji Eun KIM, Hwa Kyoung LEE, Junyeong JIN, Jong Bae PARK, Hyori KIM
  • Patent number: 11339210
    Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 24, 2022
    Assignee: Seoul National University R&DB Foundation
    Inventors: Junho Chung, Hyori Kim, Hwa Kyoung Lee, Won Jun Yang
  • Publication number: 20190382472
    Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.
    Type: Application
    Filed: April 18, 2019
    Publication date: December 19, 2019
    Applicant: Seoul National University R&DB Foundation
    Inventors: Junho Chung, Hyori Kim, Hwa Kyoung Lee, Won Jun Yang
  • Patent number: 10280215
    Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: May 7, 2019
    Assignee: Seoul National University R&DB FOUNDATION
    Inventors: Junho Chung, Hyori Kim, Hwa Kyoung Lee, Won Jun Yang
  • Patent number: 9867886
    Abstract: The present invention relates to a complex in which an anti-cotinine antibody is bound to a conjugate of a binding material and cotinine, and a use of the complex. The complex according to the present invention may be used as an analysis tool in an in vitro biological assay method, and may retain the specific reactivity and the biological function of the binding material, and the capabilities of inducing complement-mediated cell cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) and a prolonged in vivo half-life, which are intrinsic characteristics of an antibody.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: January 16, 2018
    Assignee: SNU R&DB FOUNDATION
    Inventors: Junho Chung, Sunyoung Park, Do Been Hwang, Hwa Kyoung Lee
  • Publication number: 20160068592
    Abstract: The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.
    Type: Application
    Filed: February 3, 2014
    Publication date: March 10, 2016
    Applicant: Seoul National University R&DB FOUNDATION
    Inventors: Junho CHUNG, Hyori KIM, Hwa Kyoung LEE, Won Jun YANG
  • Publication number: 20140056926
    Abstract: The present invention relates to a complex in which an anti-cotinine antibody is bound to a conjugate of a binding material and cotinine, and a use of the complex. The complex according to the present invention may be used as an analysis tool in an in vitro biological assay method, and may retain the specific reactivity and the biological function of the binding material, and the capabilities of inducing complement-mediated cell cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) and a prolonged in vivo half-life, which are intrinsic characteristics of an antibody.
    Type: Application
    Filed: April 16, 2012
    Publication date: February 27, 2014
    Applicant: SNU R&DB FOUNDATION
    Inventors: Junho Chung, Sunyoung Park, Do Been Hwang, Hwa Kyoung Lee
  • Patent number: D661995
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: June 19, 2012
    Assignee: Orion Corporation
    Inventor: Hwa Kyoung Lee
  • Patent number: D678778
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: March 26, 2013
    Assignee: Orion Corporation
    Inventor: Hwa Kyoung Lee
  • Patent number: D678779
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: March 26, 2013
    Assignee: Orion Corporation
    Inventor: Hwa Kyoung Lee
  • Patent number: D696581
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: December 31, 2013
    Assignee: Orion Corporation
    Inventor: Hwa Kyoung Lee
  • Patent number: D706640
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: June 10, 2014
    Assignee: Orion Corporation
    Inventor: Hwa-Kyoung Lee
  • Patent number: D726005
    Type: Grant
    Filed: April 26, 2013
    Date of Patent: April 7, 2015
    Assignee: Orion Corporation
    Inventor: Hwa-Kyoung Lee
  • Patent number: D733573
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: July 7, 2015
    Assignee: Orion Corporation
    Inventor: Hwa-Kyoung Lee